Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (261-270 of 275) with videos related to

Pageof 28
Sort By:
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Nature Medicine|September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialPaolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Nature Communications|March 28, 2014
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoidsLynnette Fernandez-Cuesta, Martin Peifer, Xin Lu, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Science Translational Medicine|December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerJonathan Weiss, Martin L Sos, Danila Seidel, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Pageof 28

Showing results (261-270 of 275) with videos related to

Sort By:
Pageof 28
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Nature Medicine|September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialPaolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Nature Communications|March 28, 2014
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoidsLynnette Fernandez-Cuesta, Martin Peifer, Xin Lu, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Science Translational Medicine|December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerJonathan Weiss, Martin L Sos, Danila Seidel, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Pageof 28